Personalised medicine biomarkers market to hit $58.4b by 2032

Thanks to the rising demand for targeted therapies.

The global personalised medicine biomarkers market is projected to reach $58.4b by 2032 at a compound annual growth rate of 14.54%, according to SNS Insider pvt ltd.

The sector’s expansion is attributed to the rising demand for targeted therapies, the need for early disease detection, and the emergence of novel biomarkers that allow for personalised treatment strategies.

Meanwhile, key developments include next-generation sequencing, proteomics, and bioinformatics.

Moreover, government initiatives and funding for research are further driving the market’s growth.